Staar Surgical Co (STAA) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Staar Surgical Co  (NASDAQ: STAA)

Select the Financial Report: Select the Period:


Description of Staar Surgical Co's Business Segments


Staar Surgical Company is recognized as a leader in the medical technology field, particularly in the ophthalmic sector. The company is dedicated to the design, development, manufacture, and marketing of innovative solutions, primarily focusing on intraocular lenses (IOLs), implantable collamer lenses (ICLs), and other surgical products tailored for ophthalmic surgery. Staar Surgical aims to enhance visual outcomes for patients around the globe, addressing various eye conditions, particularly cataracts and refractive errors.

Segments

Staar Surgical operates through three main segments, each tailored to meet specific clinical needs and to advance the field of ophthalmology:

1. Surgical Products:
- This segment emphasizes the innovation and provision of a broad array of IOLs essential for cataract surgery. The surgical products segment comprises several variations of IOLs:
- Aspheric IOLs: Engineered to correct spherical aberrations, these lenses enhance visual clarity, particularly in low-light conditions, benefiting patients substantially by improving contrast sensitivity.
- Toric IOLs: Specifically tailored for patients with astigmatism, these lenses correct both cataracts and astigmatism, enabling improved visual acuity without the added burden of glasses for secondary vision correction.
- Multifocal IOLs: Designed to provide simultaneous vision at multiple distances, these premium lenses cater to the needs of patients wishing to reduce their dependence on reading glasses or contact lenses.
- Extended Depth of Focus (EDOF) IOLs: Offering a continuous range of vision, these lenses facilitate clear vision from far to near, wearing less on the visual system and providing comfort across various activities and tasks.
- Implantable Collamer Lenses (ICLs): Utilized primarily for the treatment of myopia (nearsightedness) and hyperopia (farsightedness), these lenses are designed to remain in the eye permanently or until the patient chooses an alternative, offering significant correction abilities for a wide range of refractive errors.

2. Monofocal IOLs:
- This segment revolves around the production and enhancement of monofocal IOLs, which remain the most common choice in cataract surgery.
- Collamer IOLs: Staar’s flagship monofocal offering, Collamer IOLs are fabricated from a highly flexible and biocompatible material designed to integrate seamlessly with ocular tissues while providing excellent visual outcomes. Patients receiving these lenses will typically still need glasses for either distance or reading vision, but they offer a dependable and effective solution for cataract surgery.

3. End-user Products:
- This segment is committed to supporting ophthalmologists by providing a suite of products and services designed to enhance surgical practice and patient care.
- IOL Calculation Software: This cutting-edge software assists ophthalmologists in accurately calculating the power of the IOL required for each patient, ensuring tailored visual outcomes based on individual eye measurements and corneal characteristics.
- Cataract Surgery Equipment: A comprehensive range of surgical tools and techniques is made available, including phacoemulsification systems—devices that facilitate the safe removal of cataracts—and viscoelastic agents utilized during surgery to maintain the anterior chamber and protect ocular tissues.
- Training and Support Services: Staar Surgical is dedicated to providing thorough training and ongoing support for its products, enabling eye care professionals to integrate advanced IOL technology into their surgical practices effectively and optimizing patient outcomes.
- Patient Education Materials: The company develops informative materials that empower patients by providing them with essential knowledge about their eye conditions, possible treatments, and the benefits and implications of various IOL options, ultimately guiding them to make informed decisions regarding their eye care.

Conclusion

Staar Surgical Company epitomizes innovation in the ophthalmic sector, presenting an expansive portfolio of premium products and services. With a steadfast commitment to enhancing visual health through advanced technology and education for both practitioners and patients, Staar Surgical is positioned as a key player in the ongoing evolution of ophthalmic care, specifically addressing cataracts and refractive errors. Their contributions are integral to improving surgical outcomes and patient satisfaction in eye care worldwide.


Composition of Staar Surgical Co Revenues by Segments

 
CN    106.68 % of total Revenue
Geographic Distribution Domestic    13.6 % of total Revenue
Geographic Distribution Foreign    186.38 % of total Revenue
Geographic Distribution Foreign JAPAN    13.12 % of total Revenue

Q2 three months ended (Jul 03 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
CN 99.78 106.68 %
Geographic Distribution Domestic 12.72 13.6 %
Geographic Distribution Foreign 174.34 186.38 %
Geographic Distribution Foreign JAPAN 12.27 13.12 %
Total 93.54 100 %




Q2 three months ended (Jul 03 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
CN - -
Geographic Distribution Domestic 125.77 % 90.82 %
Geographic Distribution Foreign 350.65 % 100.72 %
Geographic Distribution Foreign JAPAN 12.43 % 0.05 %
Total 111.04 % 0.01 %




Q2 three months ended (Jul 03 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total 8.06 8.61 %




Q2 three months ended (Jul 03 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total - 54.78 %




Annual Report on Staar Surgical Co Divisions, Sales by Country

 
Geographic Distribution Domestic   Geographic Distribution Domestic Segment contribution to total sales 9.42 % of total Revenue
Geographic Distribution Foreign   Geographic Distribution Foreign Segment contribution to total sales 90.58 % of total Revenue
Geographic Distribution Foreign JAPAN   Geographic Distribution Foreign JAPAN Segment contribution to total sales 18.9 % of total Revenue
Non Consignment Sales   Non Consignment Sales Segment contribution to total sales 74.75 % of total Revenue
Consignment Sales   Consignment Sales Segment contribution to total sales 25.25 % of total Revenue
Geographic Distribution Foreign China   Geographic Distribution Foreign China Segment contribution to total sales 32.48 % of total Revenue
Geographic Distribution Foreign Other   Geographic Distribution Foreign Other Segment contribution to total sales 39.19 % of total Revenue
China Consignment Sales   China Consignment Sales Segment contribution to total sales 18.18 % of total Revenue


Twelve months ended 2025
STAA s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Geographic Distribution Domestic 22.56 9.42 %
Geographic Distribution Foreign 216.88 90.58 %
Geographic Distribution Foreign JAPAN 45.27 18.9 %
Total 239.44 100 %
Non Consignment Sales 178.99 74.75 %
Consignment Sales 60.45 25.25 %
Geographic Distribution Foreign China 77.78 32.48 %
Geographic Distribution Foreign Other 93.84 39.19 %
China Consignment Sales 43.53 18.18 %


Twelve months ended 2025
STAA s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total -80.45 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Total -23.72 % -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.